Annovis Bio Inc. (ANVS): Price and Financial Metrics

Annovis Bio Inc. (ANVS): $9.10

0.39 (-4.11%)

POWR Rating

Component Grades








ANVS Price/Volume Stats

Current price $9.10 52-week high $23.89
Prev. close $9.49 52-week low $8.94
Day low $8.94 Volume 27,300
Day high $9.56 Avg. volume 55,412
50-day MA $11.93 Dividend yield N/A
200-day MA $14.06 Market Cap 82.01M

ANVS Stock Price Chart Interactive Chart >

Annovis Bio Inc. (ANVS) Company Bio

Annovis Bio, Inc. develops drugs for Alzheimer's and Parkinson's diseases and other neurodegenerative disorders. It offers posiphen compound for mild cognitive impairment and early stage Alzheimer's disease and bisnorcymserine compound that inhibits amyloid formation and prevents the progression of the Alzheimer's disease. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.

ANVS Latest News Stream

Event/Time News Detail
Loading, please wait...

ANVS Latest Social Stream

Loading social stream, please wait...

View Full ANVS Social Stream

Latest ANVS News From Around the Web

Below are the latest news stories about ANNOVIS BIO INC that investors may wish to consider to help them evaluate ANVS as an investment opportunity.

Karuna (KRTX) Submits NDA Filing to FDA for Schizophrenia Drug

If approved, Karuna's (KRTX) KarXT will be the first new mechanism of action to treat schizophrenia in several decades. Data from three clinical studies support the FDA filing.

Yahoo | September 29, 2023

Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies

Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.

Yahoo | September 25, 2023

FDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney Disease

Following the latest approval, Lilly's (LLY) Jardiance can access a target market that affects more than 35 million adults in the United States.

Yahoo | September 25, 2023

Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug Study

Data from a confirmatory study shows that Travere's (TVTX) IgAN therapy did not achieve one of its confirmatory secondary endpoints. This will likely hurt the company's chances for the drug's full approval.

Yahoo | September 22, 2023

Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze

The approval is based on data from a phase II/III study, which showed that treatment with Jazz's (JAZZ) Enrylaze achieved sustained asparagine activity in two cancer indications.

Yahoo | September 22, 2023

Read More 'ANVS' Stories Here

ANVS Price Returns

1-mo -26.26%
3-mo N/A
6-mo -25.65%
1-year -33.58%
3-year 82.73%
5-year N/A
YTD -32.24%
2022 -23.61%
2021 133.16%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!